Abstract
Up-regulation of long non-coding RNAs (lncRNAs), colon-cancer associated transcript (CCAT) 1 and 2, was associated with worse prognosis in colorectal cancer (CRC). Nevertheless, their role in predicting metastasis in early-stage CRC is unclear. We measured the expression of CCAT1, CCAT2 and their oncotarget, c-Myc, in 150 matched mucosa-tumour samples of early-stage microsatellite-stable Chinese CRC patients with definitive metastasis status by multiplex real-time RT-PCR assay. Expression of CCAT1, CCAT2 and c-Myc were significantly up-regulated in the tumours compared to matched mucosa (p < 0.0001). The expression of c-Myc in the tumours was significantly correlated to time to metastasis [hazard ratio = 1.47 (1.10-1.97)] and the risk genotype (GG) of rs6983267, located within CCAT2. Expression of c-Myc and CCAT2 in the tumour were also significantly up-regulated in metastasis-positive compared to metastasis-negative patients (p = 0.009 and p = 0.04 respectively). Nevertheless, integrating the expression of CCAT1 and CCAT2 by the Random Forest classifier did not improve the predictive values of ColoMet19, the mRNA-based predictor for metastasis previously developed on the same series of tumours. The role of these two lncRNAs is probably mitigated via their oncotarget, c-Myc, which was not ranked high enough previously to be included in ColoMet19.
Introduction
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, primarily driven by the spread of the disease to distant organs. For patients diagnosed with early-stage (Stage I or II) CRC, surgical intervention is often considered curative. However, approximately 25% of these patients experience metastatic recurrence within five years. Identifying high-risk individuals in this early-stage cohort is critical for administering life-saving adjuvant therapy while sparing low-risk patients from unnecessary toxicity. This study investigates whether the inclusion of enhancer-derived long non-coding RNAs (lncRNAs)—specifically CCAT1 and CCAT2—and their target gene c-Myc can enhance the predictive accuracy of ColoMet19, an established mRNA-based predictive signature.
Methods
The study utilized a specialized cohort of 150 matched pairs of tumor and normal mucosa samples from Chinese patients with microsatellite-stable (MSS) CRC. After rigorous quality control, 143 samples (46 metastasis-positive and 97 metastasis-negative) were analyzed.
- Expression Profiling: Multiplex real-time RT-PCR (Taqman assays) was used to quantify the expression of CCAT1, CCAT2, and their oncotarget, c-Myc.
- Genotyping: SNP rs6983267, a known CRC risk variant, was genotyped using TaqMan assays and Sanger sequencing.
- Machine Learning: A Random Forest classifier was employed to rank features and determine if adding lncRNA data improved the performance of the ColoMet19 signature.
- Statistical Analysis: Cox regression and Kaplan-Meier plots were used to evaluate time-to-metastasis and metastasis-free survival.
Results
Significant Upregulation in Tumor Tissue
The expression levels of CCAT1, CCAT2, and c-Myc were found to be significantly higher in tumor tissues compared to their matched normal mucosa counterparts ($p < 0.0001$). This dramatic upregulation, often reaching several hundred-fold, confirms the strong association of these markers with the oncogenic state in colorectal tissue.
Metastasis Correlation and Predictive Stagnation
While c-Myc ($p = 0.009$) and CCAT2 ($p = 0.04$) showed significantly higher expression in patients who eventually developed metastasis, CCAT1 did not exhibit a statistically significant difference between metastasis-positive and metastasis-negative groups ($p = 0.1187$).
Crucially, the integration of these lncRNAs into the Random Forest model resulted in zero improvement in predictive metrics. The Area Under the Curve (AUC) remained stagnant at 0.78, with the Positive Predictive Value (PPV) at 0.66 and Negative Predictive Value (NPV) at 0.86. In feature importance rankings across 196 interrogated genes, c-Myc, CCAT2, and CCAT1 ranked 158th, 170th, and 195th, respectively.
Discussion
The failure of CCAT1 and CCAT2 to improve the ColoMet19 model suggests a biological redundancy. The regulatory influence of these lncRNAs is likely mediated through their downstream target, c-Myc. Because many c-Myc regulated genes are already represented in the ColoMet19 signature, the lncRNAs provide no additional independent information for the classifier. Furthermore, the study confirmed that the "G" risk allele of SNP rs6983267 functions as a super-enhancer for c-Myc expression, independent of CCAT2 transcription.
These findings highlight the complexity of using lncRNAs as independent biomarkers and suggest that while these specific markers are biologically significant, they do not currently offer the non-redundant predictive power required for routine clinical implementation in early-stage CRC metastasis screening.
Summary updated